Addition of Metastasis-Directed Therapy Increases PFS in Prostate Cancer
THURSDAY, April 13, 2023 (HealthDay News) -- The addition of metastasis-directed therapy (MDT), consisting of definitive radiation therapy to all sites of disease, to hormone therapy results in improved progression-free survival for men with oligometastatic prostate cancer, according to a study published online April 6 in JAMA Oncology.
Chad Tang, M.D., from The University of Texas MD Anderson Cancer Center in Houston, and colleagues examined whether the addition of MDT to intermittent hormone therapy improves oncologic outcomes compared to intermittent hormone therapy alone among men with oligometastatic prostate cancer in a phase 2 randomized trial. Men aged 18 years or older with oligometastatic prostate cancer with five or fewer metastases who were treated with hormone therapy for two or more months were enrolled and randomly assigned to MDT or hormone therapy alone (43 and 44 patients, respectively) and were followed for a median of 22.0 months.
The researchers found that progression-free survival was improved in the combined therapy arm compared with the hormone therapy-only arm (median, not reached versus 15.8 months; hazard ratio, 0.25). In addition, eugonadal progression-free survival was improved with MDT versus hormone therapy only (median, not reached versus 6.1 months; hazard ratio, 0.32).
"This therapeutic strategy leveraged the noninvasiveness of radiation and ability of hormone therapy to enhance radiation benefit while limiting the duration of medical castration," the authors write. "Additional studies in a more homogeneous patient population will be necessary to identify predictive biomarkers, optimize systemic therapy regimens and imaging, and identify candidate immunotherapies to exploit the favorable immunologic stimulation with MDT."
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Searching for Good Sleep? Here’s What You’re Doing Right – and Wrong
MONDAY, Feb. 7, 2022 (HealthDay News) -- Many Americans are working hard to get...
Más de la mitad de los sobrevivientes a la COVID-19 desarrollarán la ‘COVID prolongada’
JUEVES, 14 de octubre de 2021 (HealthDay News) -- Los síntomas a largo plazo de...
アトピー性皮膚炎は片頭痛の新規発症のリスク因子か
成人のアトピー性皮膚炎(AD)患者では、片頭痛を新たに発症するリスクが有意に高いという研究結果が、「Journal of the European...
Prototype Digital Therapeutic Shows Promise for Tinnitus
FRIDAY, Aug. 19, 2022 (HealthDay News) -- For patients with tinnitus, a...